Rosalind Advisors’s OptiNose OPTN Stock Holding History

Rosalind Advisors’s Portfolio OPTN Stock Details OPTN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-256,190	Closed	-$2.35M	–	44
2025 Q1	$2.35M	Sell	256,190 -620,806	-71%	-$3.9M	1.14%	25
2024 Q4	$5.86M	Buy	876,996 +324,496	+59%	+$2.86M	3%	14
2024 Q3	$5.55M	Buy	552,500 +49,357	+10%	+$720K	3.55%	12
2024 Q2	$7.85M	Buy	503,143 +200,377	+66%	+$3.36M	6.04%	4
2024 Q1	$6.63M	Sell	302,766 -22,939	-7%	-$509K	6.2%	4
2023 Q4	$6.3M	Buy	+325,705	New	+$5.94M	5.19%	7

Rosalind Advisors's OPTN Position: Q2 2025 in Review

Rosalind Advisors sold out of OptiNose (OPTN) in Q2 2025, closing a stake of 256,190 shares — an estimated $2.35M sold.

Rosalind Advisors first reported a position in OPTN in Q4 2023 and held it in 6 quarters. The position peaked at $7.85M in Q2 2024. 0 funds tracked by Wall St. Rank hold OPTN as of Q2 2025.

Rosalind Advisors reported no remaining OptiNose position as of Q2 2025 after selling out during the quarter.
Rosalind Advisors sold 256,190 OptiNose shares in Q2 2025, an estimated $2.35M.
Rosalind Advisors first reported a position in OptiNose in Q4 2023 and held it in 6 quarters.
Rosalind Advisors's OptiNose position peaked at $7.85M in Q2 2024.
0 funds tracked by Wall St. Rank held OptiNose as of Q2 2025.

Based on Rosalind Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.